Cipla has entered into an agreement with Roche Pharma, under which Cipla will be promoting and distributing Tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.

Cipla MD & Global CEO, Umang Vohra stated, “The prevalence of cancer and rheumatoid arthritis is widely spread across India, and Cipla can contribute to provide broader access to innovative medicines like tocilizumab and bevacizumab. We look forward to promote and distribute the drugs in India in furtherance to our philosophy of Caring for Life.”

Read EquityPandit’s Technical Analysis of Cipla